Synthetic 'SpudCell' sparks debate over medical promise and bioethical risks
Researchers have built a lab-crafted synthetic cell called SpudCell, which can perform limited cellular functions, prompting excitement about therapeutic uses and concern over safety and ethical implications.
A team led by synthetic biologist Kate Adamala at the University of Minnesota has created SpudCell, a synthetic construct that mimics several core functions of living cells using assembled biomolecules. Advocates argue that these artificial cells could serve as precise drug carriers, generate essential therapeutics such as insulin or antibiotics inside patients, and provide autonomous medical support for astronauts on deep-space missions.
They also envision environmental applications like breaking down pollutants or cleaning oil spills. Opponents caution that the same capabilities could be weaponized, and that synthetic cells might outcompete natural microbes, especially if they possess altered enzymes that evade immune detection. Moreover, SpudCell cannot sustain indefinite replication because it lacks ribosome production and a robust metabolism, requiring a nutrient broth and external ribosomes, and it does not reliably transmit genetic traits to progeny, as noted by bioengineer Tara Daens.
Why it matters
Synthetic cells could transform medicine and environmental remediation, but also raise serious biosecurity and ecological risks.
In this story
